HC Wainwright & Co. Maintains Buy on Candel Therapeutics, Lowers Price Target to $18

Benzinga · 14h ago
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $23 to $18.